{"name":"Sight Sciences","slug":"sight-sciences","ticker":"SGHT","exchange":"NASDAQ","domain":"sightsciences.com","description":"Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult pat","hq":"Menlo Park, CA","founded":0,"employees":"186","ceo":"Paul Badawi","sector":"Ophthalmology / Medical Devices","stockPrice":5.21,"stockChange":0.31,"stockChangePercent":6.33,"marketCap":"$283M","metrics":{"revenue":79553000,"revenueGrowth":12.5,"grossMargin":86.2,"rdSpend":14606000,"netIncome":-38426000,"cash":84962000,"dividendYield":0,"peRatio":-7.9,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Latanoprost plus adjunctive glaucoma medication","genericName":"Latanoprost plus adjunctive glaucoma medication","slug":"latanoprost-plus-adjunctive-glaucoma-medication","indication":"Open-angle glaucoma","status":"marketed"}]}],"pipeline":[{"name":"Latanoprost plus adjunctive glaucoma medication","genericName":"Latanoprost plus adjunctive glaucoma medication","slug":"latanoprost-plus-adjunctive-glaucoma-medication","phase":"marketed","mechanism":"Latanoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to lower intraocular pressure in glaucoma, combined with an adjunctive agent to enhance this effect.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Sight Sciences reported revenue of $43.8 million for the fourth quarter and $153.4 million for the full year 2023, exceeding expectations.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Sight Sciences Announces Collaboration with Alcon to Develop Next-Generation Glaucoma Treatment","summary":"Sight Sciences partnered with Alcon to develop a new glaucoma treatment, expanding their product portfolio and market reach.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Sight Sciences Receives FDA Clearance for OMNI Surgical System","summary":"Sight Sciences received FDA clearance for their OMNI Surgical System, expanding their product offerings and market presence.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxORjJBdXctdXhiS0gwTEZjX1N1NUpEdjJxaE5xTmE4aFN6VDY0eWQ2NlhrSWt6cXk4VHdpTTZQeEg4c0o3c0h2dGlqWV81YXNKWF9Zdks0aWRUWVI0TS1sWGdaM1BpNkI1c09YZTlKQTM2alluWmJ3Y2I4NG16eWJ6MGFWeUl4ZjNPY0RUc2xBbV9qek9SdERrZ3M4S0YyS3NaQjZGTUF6VU5BWHllYmZaS0ln?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Sight Sciences (SGHT) CTO tax-related sale of 8,168 shares disclosed - Stock Titan","headline":"Sight Sciences (SGHT) CTO tax-related sale of 8,168 shares disclosed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNVTJJX29uU2tNUVFDWDFPNGxPSU5GdDhQbzBjeU1FVUllQmhrOXFTd2xtMWhJaXJ5VWVLWFhaUWJFVnFubXhVLXhaQjRxTmRlMm93cVZmMmpFOXZmZWwtMGp2QlZOMXNPUEkxZi0tQUlkZkJES2dTS29NQTZXSVBodENqSXpnVXFXeW93bTlocGFHZ256MVNMeTlQRjR5a0RoeVpyczZuYVI3XzJvV2stR3J3?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Sight Sciences (SGHT) EVP Brenton sells 2,869 shares for RSU tax obligations - Stock Titan","headline":"Sight Sciences (SGHT) EVP Brenton sells 2,869 shares for RSU tax obligations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYm83QjVENGJLR0dWYXNXcVRWbmF5T25QUjFsb0pxM2VOR050ZmdNWnZ3T1dMQ3pXam9XUjhOZTN2QndscHNfSklkV3lLRkZZdW9yR25vT05GMHJpb3J5eG44eDl0UHBWTzFUcUdFb25RcGlnQXdHbGYySkdLSTlsZkZIUUNYZnVvdEE4b1FrdnNyOEp5c0tvOUR5Z1YyOFE2Xzk1VjNCQjB3U0U?oc=5","date":"2026-03-30","type":"pipeline","source":"Stock Titan","summary":"Sight Sciences (NASDAQ: SGHT) awarded $34M plus 10% Hydrus royalties - Stock Titan","headline":"Sight Sciences (NASDAQ: SGHT) awarded $34M plus 10% Hydrus royalties","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxQS3R5NjVPTzVFeFhzZU4xa0FlcFB1ZVJGcUhlWFlXRFAtZmR6SVkxWGVfY0FvVjJsSGhCN0p3NHE5aTR6aDVxeDA3MlVpcGhRZWRKT1pITER4WHhzcTBmSVlJN2VNYzlndE94bWRjcUVDaW5QNnByeWpWVnpKSXp0Zm01UkJDallSMWtLdG4wOTZfQlNaUnNMQTNyNzU1akgtQ09jYktIWktWaFVKVDJxVTJNTk9fZ2FxbWJYWlJSX3RyUXlyZ3ZwTUtpcmtpS2tCUHBKMGl4MmFya2hxM2NxMjBlLVpjNHk1d25CT1J2TzhNeVpQVmQxMGpGaEdxcUZ6NzBZd3JMQk1rcVRWbjFKa0R3czBDNnExUUVrdG1xODR5WGxkVHZaRXVVTjBlZ0RkaHpkTUY2LVFtbjEzZzRTeG9ob1dKb3NpSFRlYlpzc0ZxQzhNWTBfa1h5enU4anc?oc=5","date":"2026-03-30","type":"trial","source":"GlobeNewswire","summary":"Sight Sciences Secures Order on Post-Trial Motions That - GlobeNewswire","headline":"Sight Sciences Secures Order on Post-Trial Motions That","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTnRNMy1LazFIUFZScFNFRzM0dmRwekxKcFR4bmt6R2dyTGtMTkhCU3d2MlBUbDJZVFNKSG9HVTZBU1pwUFhCc3E2amN5TFpQeG5RTmV0cy1NUFlmTm1EMjRBdHNubjQta3BiV2R4ZmUwbTVNV1V2OE1vR0dDZi16V3FQT1ppOU9pRC1ITkVQdFpGV21YbDJ6akJhbHU3Q1VnMFVJQTRyOTVVUQ?oc=5","date":"2026-03-06","type":"earnings","source":"Insider Monkey","summary":"Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 Earnings Call Transcript - Insider Monkey","headline":"Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 Earnings Call Transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQemxjQU1oY3lyS2hVSW5XM09jcjhEWWlXQ0FGdjNCWTJObnFRQ1FwbGNQYUNIUXpWVTNnNl9MZTNqRGlzOXhIT2NCeC1OQWpMMVMybDZSOVBVekZEZzhHS2NuTmMxV2dETWpBRVczQUsweng5VGRTOWRKNFZ4eWJwVGcyM0dMWEhCR1RzVUZjRzkzUEN6c1p1MTQ1M29aWEY1cl9MekN2NWw4S3FvSlVURHVyV3I?oc=5","date":"2026-03-05","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Thursday's Intraday Session - Can Fite Biopharma (AMEX:CANF), Gossamer Bi - Benzinga","headline":"12 Health Care Stocks Moving In Thursday's Intraday Session - Can Fite Biopharma (AMEX:CANF), Gossamer Bi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5qeWllR3BKWDl5a09DYXZ5ZjJzWEZoanZ0VUotclVjQXNtNVl3WFlscFk0cTIxZHl2bnh5ZkwwOFVZSjJfVTU1Y3BMRjdHbzNXdU4zQWtlei1zUEpTanpwQ0RqcnFyMGRuYjdId3RLbGFfMnpaVjMzMWxXcw?oc=5","date":"2026-03-04","type":"earnings","source":"AOL.com","summary":"Sight Sciences (SGHT) Q4 2025 Earnings Transcript - AOL.com","headline":"Sight Sciences (SGHT) Q4 2025 Earnings Transcript","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNcEFIR3ZfWmtvTjhGa0NTOGQ5STZPOUVWbmY2QmlzRk5id05wZVVDMl9janlHa0FuSjVwZlZrc1d1XzdxMXU0ZVFRQ1hNM20teEdUaHFobGNVd2lRcUx3T2REekMzX2hDcnNpNGtJeVZ2c29YRkgzRWZucWVHeVNCV3FIXzlULUx4MTRsbkd6aGJ2RDhzRXVXdjNJZWt5SHVGYnROZml4ejRVdjVYd2NJQVQ4YkRRYlpqTTZWVmdnRjNic2pE?oc=5","date":"2026-03-02","type":"pipeline","source":"Investing.com","summary":"Stifel raises Sight Sciences stock price target on TearCare survey - Investing.com","headline":"Stifel raises Sight Sciences stock price target on TearCare survey","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPdktjRFZQajJ3SDJkeUtZblhoZnJwUWVHazd3Y2pnVm1vcDJSMFdjY0EzOUFXcUFCM1lhWE5jNVRGLU5RLTNLM1hnSzBFUVh3c2xaSTdDSllXZ18tYnhLZEZPeW5EdXZHcllDd3pVNzZaQ3N0bzFEM0VrT2pfYms4T252cDMyU3FSWmVsMXdDYS1OZjRkTW9GN0otamZNSzd1UEUzd3lqY0F1R2UtcFRqbG1EUHh2dzg2SUp3UQ?oc=5","date":"2026-01-13","type":"pipeline","source":"Stock Titan","summary":"Eye care firm Sight Sciences reports 130% Dry Eye jump in late 2025 - Stock Titan","headline":"Eye care firm Sight Sciences reports 130% Dry Eye jump in late 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBYWmpOSU1ENm1RckFaaFdhc3hfaGVINklxSk1OSGNydUdZQW14cWxrSmgzbmhQb0hiamc5VFNHM01WUmVweEdHalM0OUU4dXFlQlNZSjRSOUlJSk1RQmRlTE4wY0RBMDRlT3Q2VjFDUnl5OXhMLTZj?oc=5","date":"2025-09-17","type":"trial","source":"MassDevice","summary":"Sight Sciences reports positive data for Omni surgical system - MassDevice","headline":"Sight Sciences reports positive data for Omni surgical system","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNR2VKWTdWcWRYci1vV20tRzlFRnJ0VDlGaGd0NnFrdk43SFZTWXlUcWh3WFIxN19EaTk1WGRLYVNpQzZ1UF81Zl9qVDdhVTJaNWg4LTVVbDB3dDY3QTM3QjlyS3VNSE10UjBwMk51Y1NfelRDLWNKRVBWU0pIdXdraUhHTXRMZWNRMWlrbER2RlF2NFk0Nms0SDRacWRKRXAtenhNbQ?oc=5","date":"2025-08-28","type":"pipeline","source":"Seeking Alpha","summary":"Sight Sciences Trying To Thread An Increasingly Narrow Needle (NASDAQ:SGHT) - Seeking Alpha","headline":"Sight Sciences Trying To Thread An Increasingly Narrow Needle (NASDAQ:SGHT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPQWpoZmtfMjJmOVBBQXZHWmFDdlFwSldZRHRUQVNuRnlhY3JGMjZzZTh1XzNJZkV3akRMMW5mZmFlWThFUVU2dU05cVBaTDdpQ29VMERjdVJqbk1vc3hVOFJvcnZYcUc0Um1Oc19oeWJWdFFSQWpTY0kwNWtoNUhyNWE1VnZyT2V2THVoTmY0VlhpSW0xc1h0LVNKSFYzd3BMY2FJV2k0QjRDQ0Q2QkduUThJSDYwbHhsWnRLUlJYMnlwN3N5?oc=5","date":"2025-03-05","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Sight Sciences Q4 2024 results miss forecasts - Investing.com","headline":"Earnings call transcript: Sight Sciences Q4 2024 results miss forecasts","sentiment":"negative"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Johnson & Johnson","Abbott Laboratories"],"therapeuticFocus":["Glaucoma","Ophthalmology"],"financials":{"source":"sec_edgar+yahoo","revenue":77363000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":77363000,"period":"2025-12-31"},{"value":79866000,"period":"2024-12-31"},{"value":79866000,"period":"2024-12-31"},{"value":81056000,"period":"2023-12-31"},{"value":81056000,"period":"2023-12-31"}],"grossProfit":66666000,"grossProfitHistory":[{"period":"2025-12-31","value":66666000},{"period":"2024-12-31","value":68285000},{"period":"2023-12-31","value":69175000},{"period":"2022-12-31","value":58970000}],"rdSpend":14606000,"rdSpendHistory":[{"period":"2025-12-31","value":14606000},{"period":"2024-12-31","value":17991000},{"period":"2023-12-31","value":17556000},{"period":"2022-12-31","value":22859000}],"sgaSpend":89159000,"operatingIncome":-37099000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-37099000},{"period":"2024-12-31","value":-50532000},{"period":"2023-12-31","value":-57274000},{"period":"2022-12-31","value":-83954000}],"netIncome":-38426000,"netIncomeHistory":[{"period":"2025-12-31","value":-38426000},{"period":"2024-12-31","value":-51507000},{"period":"2023-12-31","value":-55547000},{"period":"2022-12-31","value":-86242000}],"eps":-1.03,"epsHistory":[{"period":"2024-12-31","value":-1.03},{"period":"2023-12-31","value":-1.14},{"period":"2022-12-31","value":-1.8},{"period":"2021-12-31","value":-2.36}],"cash":91965000,"cashHistory":[{"period":"2025-12-31","value":91965000},{"period":"2024-12-31","value":120357000},{"period":"2023-12-31","value":138129000},{"period":"2022-12-31","value":185000000}],"totalAssets":115300000,"totalLiabilities":51358000,"totalDebt":40775000,"equity":63942000,"operatingCashflow":-29694000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-29694000},{"period":"2024-12-31","value":-22351000},{"period":"2023-12-31","value":-47184000},{"period":"2022-12-31","value":-75965000}],"capex":-224000,"capexHistory":[{"period":"2025-12-31","value":-224000},{"period":"2024-12-31","value":-385000},{"period":"2023-12-31","value":-791000},{"period":"2022-12-31","value":-970000}],"freeCashflow":-29918000,"dividendsPaid":null,"buybacks":null,"employees":186,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":19020000,"ebit":-2865000,"ebitda":-2757000,"period":"2025-12-31","revenue":20385000,"epsBasic":-0.08,"netIncome":-4162000,"rdExpense":2437000,"epsDiluted":-0.08,"grossProfit":17788000,"operatingIncome":-3669000},{"sga":21750000,"ebit":-6942000,"ebitda":-6837000,"period":"2025-09-30","revenue":19906000,"epsBasic":-0.16,"netIncome":-8169000,"rdExpense":3352000,"epsDiluted":-0.16,"grossProfit":17197000,"operatingIncome":-7905000},{"sga":23867000,"ebit":-10617000,"ebitda":-10492000,"period":"2025-06-30","revenue":19564000,"epsBasic":-0.23,"netIncome":-11941000,"rdExpense":4387000,"epsDiluted":-0.23,"grossProfit":16587000,"operatingIncome":-11667000},{"sga":24523000,"ebit":-12850000,"ebitda":-12701000,"period":"2025-03-31","revenue":17508000,"epsBasic":-0.28,"netIncome":-14154000,"rdExpense":4430000,"epsDiluted":-0.28,"grossProfit":15094000,"operatingIncome":-13859000},{"sga":24197000,"ebit":-10647000,"ebitda":-10471000,"period":"2024-12-31","revenue":19074000,"epsBasic":-0.23,"netIncome":-11846000,"rdExpense":4293000,"epsDiluted":-0.23,"grossProfit":16561000,"operatingIncome":-11929000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":5.21,"previousClose":4.9,"fiftyTwoWeekHigh":9.24,"fiftyTwoWeekLow":3.11,"fiftyTwoWeekRange":"3.11 - 9.236","fiftyDayAverage":4.06,"twoHundredDayAverage":5.16,"beta":2.38,"enterpriseValue":223407712,"forwardPE":-7.9,"priceToBook":4.36,"priceToSales":3.56,"enterpriseToRevenue":2.81,"enterpriseToEbitda":-8.27,"pegRatio":0,"ebitda":-27012000,"ebitdaMargin":-34,"freeCashflow":-8579000,"operatingCashflow":-25118000,"totalDebt":41761000,"debtToEquity":77.5,"currentRatio":5.86,"returnOnAssets":-14.3,"returnOnEquity":-56.6,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":4,"targetMeanPrice":8.34,"targetHighPrice":12,"targetLowPrice":4.35,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":20,"institutionHeldPercent":51.7,"sharesOutstanding":54409942,"floatShares":35689113,"sharesShort":936889,"shortRatio":2.69,"shortPercentOfFloat":1.7,"epsTrailing":-0.7,"epsForward":-0.66,"revenuePerShare":1.51,"bookValue":1.2,"officers":[{"age":49,"name":"Mr. Paul  Badawi","title":"Co-Founder, President, CEO & Director"},{"age":44,"name":"Ms. Alison Perry Bauerlein","title":"Chief Operating Officer"},{"age":55,"name":"Mr. Jeremy B. Hayden J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":54,"name":"Dr. David  Badawi M.D.","title":"Co-Founder, CTO & Director"},{"age":41,"name":"Mr. James  Rodberg","title":"CFO & Treasurer"},{"age":null,"name":"Mr. Steve R. Tamayo Jr.","title":"VP and Chief Ethics & Compliance Officer"},{"age":44,"name":"Mr. Brenton  Taylor","title":"Executive Vice President of Operations and R&D"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.sightsciences.com","phone":"877 266 1144"}}